Remedy Health Media, a New York-based health information company, has bought HealthCentral, a start-up that offers online clinical and patient tools, community and content in a variety of topic areas.

Terms of the deal were not disclosed, but the Arlington, Va.-based HealthCentral has raised $50 million from investors such as the Carlyle Group, IAC/InterActiveCorp, Polaris Venture Partners and Sequoia Capital. Allen & Co., which was HealthCentral’s financial adviser for the transaction, was also an investor.

The market for online-based information about health has been a fast-growing one, but it’s still a nascent arena.

Here’s the official press release:

Remedy Health Media Acquires HealthCentral: Creates Industry-Leading Health Information and Technology Platform

NEW YORK, NY – Remedy Health Media, America’s fastest-growing health information and technology company, today announced its acquisition of HealthCentral, a leading provider of online clinical and patient community resources and tools that help millions of patients and caregivers take control of their health and improve their well-being. The acquisition brings together two companies with the shared mission of empowering patients and caregivers with the information and applications needed to efficiently navigate the healthcare landscape to receive better health outcomes. The acquisition is expected to close this week. Terms were not disclosed.

“This acquisition means Remedy now provides the health information industry’s leading portfolio of digital, mobile, and point-of-care information and technology products,” said Remedy Chief Executive Officer, Mike Cunnion.

HealthCentral’s CEO, Christopher M. Schroeder, adds, “This combination creates real opportunities for innovation in an industry segment that is growing rapidly and seeking new solutions. All of us at HealthCentral are very excited that the union of the two companies and the strength, scope, and reach of the new Remedy will be a unique force for better health and wellness.”

With the addition of HealthCentral, Remedy Health Media creates a market-leading platform for healthcare audiences seeking proprietary information and technology to manage their health concerns on their terms as well as marketing partners who want to connect with patients and caregivers on a number of platforms: online, in doctors’ offices, pharmacies, and through their mobile devices. The new Remedy Health Media will influence more than 150 million consumers annually. The company’s reach now includes 23 million unique monthly visitors to its health websites, more than 17 million patients and caregivers at pharmacy counters nationwide, a 20-million member customer database, and a network of more than 600,000 physicians.

“With the acquisition of HealthCentral, we’ve dramatically increased our online reach, sales capacity and our ability to create industry leading health information and technology applications,” notes Cunnion. “The combination creates exciting opportunities to provide even more value to our audiences, customers and strategic partners.”

Remedy Health Media is a Veronis Suhler Stevenson (VSS) company; a leading global private investment firm focused on the information, education, media, communications and business services industries. “Communications growth will be driven by the convergence of technologies in digital and mobile platforms,” said David Bainbridge, Managing Director, Veronis Suhler Stevenson. “Nowhere is this more evident than in the health and wellness sector where the ability to access accurate information is paramount.”

HealthCentral is backed by leading interactive media and technology investors IAC/InterActiveCorp, Polaris Ventures, Sequoia Capital, The Carlyle Group and Allen & Company. Notes Alan Spoon of Polaris Ventures, “We are thrilled to join forces with Mike and the Remedy team. This combination is a unique opportunity to create the largest and most innovative platform for health seekers looking to take action on their terms, and connecting them with our partners and clients.”

Schroeder will remain involved in the business as a consultant to Remedy and the board of directors, and has been named an Advisor to Polaris Ventures.

A growing number of American adults and children face complex medical conditions like heart disease and diabetes. They may have drug or food allergies, suffer from disorders like autism, or take medications like the blood thinner coumadin that medical staff should know about in an emergency.

New bracelets and other medical-identification systems can fill in first responders on practically a patient’s complete health history. They’re a far cry from the simple identification bracelets of the past, which with a few engraved words informed medics that a person was, perhaps, allergic to penicillin. They can steer first responders to a secure website or toll-free phone number, or initiate a text message, to get the medical and prescription history of a patient who may be unconscious or unable to talk about their condition.

Read the rest of this post on the original site

In a statement issued late Tuesday, Dr. James D. Eason, the chief of transplantation at Methodist University Hospital Transplant Institute in Memphis, said that Jobs did in fact receive a new liver at his transplant facility and is now recovering well. He also dismisses speculation that the Apple CEO’s wealth and celebrity may have afforded him early access to the organ, noting that Jobs qualified for the donor liver when he did because he was the sickest patient of his blood type at the time it became available. Below, the statement in full:

James D. Eason, M.D., program director at Methodist University Hospital Transplant Institute and chief of transplantation confirmed today, with the patient’s permission, that Steve Jobs received a liver transplant at Methodist University Hospital Transplant Institute in partnership with the University of Tennessee in Memphis.

Mr. Jobs underwent a complete transplant evaluation and was listed for transplantation for an approved indication in accordance with the Transplant Institute policies and United Network for Organ Sharing (UNOS) policies.

He received a liver transplant because he was the patient with the highest MELD score (Model for End-Stage Liver Disease) of his blood type and, therefore, the sickest patient on the waiting list at the time a donor organ became available. Mr. Jobs is now recovering well and has an excellent prognosis.

The Methodist University Hospital Transplant Institute performed 120 liver transplants in 2008 making it one of the ten largest liver transplant centers in the United States. We provide transplants to patients regardless of race, sex, age, financial status, or place of residence. Our one year patient and graft survival rates are among the best in the nation and were a dominant reason in Mr. Jobs’s choice of transplant centers. We respect and protect every patient’s private health information and cannot reveal any further information on the specifics of Mr. Jobs’s case.

In a statement issued late Tuesday, Dr. James D. Eason, the chief of transplantation at Methodist University Hospital Transplant Institute in Memphis, said that Jobs did in fact receive a new liver at his transplant facility and is now recovering well. He also dismisses speculation that the Apple CEO’s wealth and celebrity may have afforded him early access to the organ, noting that Jobs qualified for the donor liver when he did because he was the sickest patient of his blood type at the time it became available. Below, the statement in full:

James D. Eason, M.D., program director at Methodist University Hospital Transplant Institute and chief of transplantation confirmed today, with the patient’s permission, that Steve Jobs received a liver transplant at Methodist University Hospital Transplant Institute in partnership with the University of Tennessee in Memphis.

Mr. Jobs underwent a complete transplant evaluation and was listed for transplantation for an approved indication in accordance with the Transplant Institute policies and United Network for Organ Sharing (UNOS) policies.

He received a liver transplant because he was the patient with the highest MELD score (Model for End-Stage Liver Disease) of his blood type and, therefore, the sickest patient on the waiting list at the time a donor organ became available. Mr. Jobs is now recovering well and has an excellent prognosis.

The Methodist University Hospital Transplant Institute performed 120 liver transplants in 2008 making it one of the ten largest liver transplant centers in the United States. We provide transplants to patients regardless of race, sex, age, financial status, or place of residence. Our one year patient and graft survival rates are among the best in the nation and were a dominant reason in Mr. Jobs’s choice of transplant centers. We respect and protect every patient’s private health information and cannot reveal any further information on the specifics of Mr. Jobs’s case.